Baliopharm AG was founded in 2007 and is based in Reinach, Switzerland.

In April 2022, Baliopharm successfully completed Phase 1 clinical trials with the antibody Atrosimab, an antagonist of the TNFR1 receptor. Atrosimab is suitable for the treatment of a variety of acute and chronic inflammatory diseases. Xlife Sciences does not hold any equity interest in Baliopharm AG but instead receives a specific percentage of the annual net revenue that Baliopharm generates from the sale or licensing of Atrosimab.